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Diffuse parenchymal lung diseases (DPLD) represent a diverse group of disorders affecting the distal lung
parenchyma, specifically the tissue and spaces surrounding the alveoli, which may be filled with inflammatory cells,
proliferating fibroblasts or established fibrosis, often leading to architectural distortion and impaired gas exchange.
While the underlying pathogenetic mechanisms are known or inferred for some DPLD (such as sarcoidosis, silicosis,
drug reactions and collagen vascular diseases), the pathogenesis of the majority of these entities - particularly those
characterized by progressive fibrosis - is poorly understood.
Several lines of evidence indicate that the development of pulmonary fibrosis is genetically determined. They
include: 1. familial clustering; 2. the occurrence of pulmonary fibrosis in the context of rare inherited disorders; 3.
substantial variability in the development of pulmonary fibrosis amongst individuals exposed to organic or
inorganic dusts; 4. difference in susceptibility to fibrogenic stimuli amongst inbred strains of mice.
This review focuses on idiopathic pulmonary fibrosis (IPF) and sarcoidosis, the two most common DPLD and the
two entities for which there is stronger evidence of a genetic predisposition, although how aberrant genes interact
with each other and with environmental factors, such as smoking in IPF and infectious agents in sarcoidosis, in
determining disease susceptibility and clinical phenotypes is largely unknown. Finally, we discuss practical issues
and implications for both patients and physicians of recent advances in the genetics of sarcoidosis and IPF.
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Physicians experienced in diffuse parenchymal lung dis-
eases (DPLD) know that these disorders may run in
families. DPLD are thought to be complex diseases,
resulting from genetic variations relatively common in
the general population and involving multiple genes,
each contributing an effect of varying magnitude. How-
ever, an individual may have the necessary genetic profile
to develop a disease and yet it will not manifest unless an
environmental or infectious factor is encountered. In addi-
tion, the relative contribution of genes and environment is
likely to vary in different conditions. On the other hand,
the association of surfactant protein (SFTP)-C (SFTPC),
SFTPA2, Telomerase Reverse Transcriptase (TERT), and
Telomerase RNA (TERC) mutations with familial pul-
monary fibrosis (FPF) demonstrate that a single variation* Correspondence: paolo.spagnolo@unimore.it
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reproduction in any medium, provided the ormay be the cause of the disease. Yet, the phenotypic het-
erogeneity observed among affected family members sug-
gests that the underlying genetic abnormality(ies) may
only confer a generic predisposition to “pulmonary fibro-
sis”; in such case, the phenotypic variability could be
determined by the interaction of a single genetic
abnormality with either different triggers (injuries/
fibrogenic agents) or multiple genetic variations of smaller
effects. These two pathogenetic hypotheses are not
mutually exclusive.
Inheritance patterns of complex diseases are often
unusual. Indeed, although many of them cluster in
families, suggesting that genetics plays a major role in
disease risk, not all family members are affected.
Furthermore, determining a true genetic association is pro-
blematic because families share more than just their genes.Complex versus single-gene disorders
Single-gene and complex diseases are both characterized
by multiple genetic and environmental factors. However,ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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effect in determining the phenotype, and may override
the effects of products of other loci. Conversely, in
complex diseases the phenotype results from multiple
gene products combined with environmental factors.
Modifying genes and genetic heterogeneity can make
single-gene disorders complex but not as multifactorial
as diseases that involve multiple genes and multiple
environmental variables.
The main difference between single-gene and complex
disorders is therefore the extent to which a single gene
product disrupts homeostasis. If the gene product is so
deficient or defective that it causes severe damage to the
system in which it functions, the disease is generally rare
and will nearly always have an early onset. Conversely, if
a gene product functions adequately under most circum-
stances but does not when other gene products with
which it is integrated fail to function, the resulting dis-
ease will be more frequent and will generally develop
gradually, often presenting in middle age. Explanation of
causation and determination of disease risk is more pro-
blematic with complex than with single-gene disorders.
In fact, the disease risk imparted by the same gene pro-
duct(s) can differ from family to family, and even
amongst members of the same family, owing to hetero-
geneity of genes and environmental exposures (which
may precipitate the disease). Table 1 summarizes the
main difference between complex and single-gene
disorders.Lung fibrosis. Identification of predisposing genetic
factors
Fibrosis is defined by the overgrowth, hardening and/or
scarring of various tissues and is attributed to excess
deposition of extracellular matrix components. FibrosisTable 1 Complex versus single-gene disorders











Important Often overridden by
effect(s) of gene
mutation
Age of onset Often older Often younger







Healthcare burden High Relatively low





Generally less variableis commonly the end result of chronic inflammatory reac-
tions induced by a variety of stimuli including persistent
infections, autoimmune reactions, allergic responses, che-
mical insults, radiation, and tissue injury [1]. However,
while this may hold true for many fibrotic DPLD, the
contribution of chronic inflammation in idiopathic
pulmonary fibrosis (IPF) is minimal, if any, the main
argument being the failure of anti-inflammatory and
immunomodulatory agents to significantly influence the
course of the disease.
The existence of a genetic predisposition to lung fibro-
sis is suggested by a number of factors. They include:
the considerable variability in developing lung fibrosis in
individuals exposed to fibrogenic dusts, such as silica
and asbestos, the differential response to experimentally-
induced fibrosis observed in inbred mouse strains and
the occurrence of pulmonary fibrosis in the context of
several pleiotropic genetic disorders, such as dyskerato-
sis congenita, Niemann-Pick disease and Hermansky-
Pudlak syndrome, amongst others [2]. However, the
most persuasive evidence of a genetic signature in DPLD
comes from family studies, particularly in idiopathic
interstitial pneumonia (IIP) and sarcoidosis where famil-
ial aggregation has been confirmed through studies in
twins, siblings raised apart, and multigenerational
families [3]. The most likely mode of genetic transmis-
sion of pulmonary fibrosis in familial cases is autosomal
dominant with variable penetrance [4].
Idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF; ORPHA2032) is the
most common of the idiopathic interstitial pneumonias.
The histopathologic hallmark is a heterogeneous appear-
ance in which areas of fibrosis with scarring and honey-
comb change alternate with areas of less affected or
normal parenchyma (so called usual interstitial pneumo-
nia - UIP - pattern). According to the prevailing hypoth-
esis, IPF develops as a result of excessive, sequential
lung injury and aberrant wound healing. Patients usually
present with progressive dyspnoea, chronic dry cough,
reticular infiltrates on chest X-ray or chest high-
resolution computed tomography (HRCT) and a restric-
tive ventilatory defect with decreased diffusion capacity
for carbon monoxide. Clinical trials of some therapeutic
agents suggest a possible benefit, although to date there
is insufficient evidence to support the use of any specific
pharmacologic therapy for patients with IPF [5].
Familial pulmonary fibrosis
The occurrence of IPF in two or more members of the
same family is well established, accounting for 5% of
total IPF cases [6,7]. Familial and sporadic IPF are clini-
cally and histologically indistinguishable, although familial
forms may develop at an earlier age [6] and seem to have
Spagnolo et al. Orphanet Journal of Rare Diseases 2012, 7:79 Page 3 of 8
http://www.ojrd.com/content/7/1/79different patterns of gene transcription [8]. Cigarette
smoking appears to be a risk factor for the development
of the disease in FPF, suggesting that environmental/
occupational exposures may accentuate genetic risk and
that gene-environment interactions may be critical in
IPF pathogenesis. Another remarkable finding is the
pathologic heterogeneity within family members. In fact,
while 50% of the families have a “uniform” diagnosis of
UIP/IPF, the remaining 50% display radiological or
pathologic features suggestive of a different IIP in at
least one affected family member [3].
Surfactant protein C mutations
Mutations within surfactant protein C (SFTPC) have been
consistently associated with FPF. Of these, the substitution
of glutamine for leucine at aminoacid 188 (L188Q) in the
pro-SPC protein is the most extensively studied owing to
its functional relevance. In fact, while pro-SPC is normally
processed through multiple steps and secreted into the
alveolar space [9], L188Q mutated pro-SPC is not pro-
cessed and folded correctly in the endoplasmic reticulum
(ER), leading to protein accumulation and ER stress. This,
in turn, activates a cascade of events known as unfolded
protein response (UPR), a mechanism which, although
designed to protect the cell, may become deleterious and
lead to alveolar epithelial cell (AEC) apoptosis in case of
long-standing or severe activation [10,11]. ER stress, UPR
activation and AEC apoptosis have been reported in
sporadic IPF, suggesting a key pathogenetic role [12].
Similarly, mutations within SFTPA2 appear to predispose
to FPF through retention of the mutant SPA form in the
ER and subsequent ER stress [13,14].
Telomerase mutations
Telomeres - the tandem repeats of TTAGGG - represent
a molecular cap of non coding DNA that protects the
ends of the chromosomes against degradation. With
repeated cell division, telomeres tend to shorten and
chromosomes may become unstable, fused, or lost, lead-
ing to cell apoptosis. A complex of proteins and RNA
called telomerase is essential in maintaining telomere
length: the reverse transcriptase component TERT and
the telomerase RNA template component TERC are key
components of the telomerase complex [15].
Dyskeratosis congenita, a rare hereditary disorder
complicated by the development of pulmonary fibrosis
in 20% of patients, is associated with mutations within
either TERT [16] or TERC [17] that lead to decreased
telomerase activity. Recent data suggest that in a sizeable
proportion of patients IPF is a disease of telomere main-
tenance. Mutations in TERT and TERC account for 8-
15% of familial and 1-3% of sporadic cases [18,19], but
short telomere length is a more common finding in IPF
- with sporadic IPF cases displaying significantly shortertelomeres compared to age-matched controls - even in
the absence of telomerase mutations [20]. Further, there
is evidence that reduced telomere length may be a risk
factor for disease outside the lung, such as liver cirrhosis
or diabetes, both occurring in IPF patients at a fre-
quency higher than expected [20,21].
Mucin genes
MUC5AC and MUC5B are the major gel-forming
mucins found in human airway secretions. In a genome-
wide linkage scan and subsequent fine mapping of a risk
locus on 11p15.5, the minor allele of a common variant
(rs35705950) within MUC5B has been found to be pre-
sent in 34% of FPF cases, 38% of IPF cases and 9% of
controls [22]. The rs35705950 mutant allele is associated
with up-regulation of MUC5B expression in the lung,
specifically in lesions of IPF, suggesting that dysregulated
MUC5B expression in the lung may be involved in the
pathogenesis of pulmonary fibrosis [23]. Although aber-
rant MUC5B is a plausible candidate, either by impairing
mucosal host defense or interfering with alveolar repair,
it is possible that unscreened genetic variants (especially
in the inaccessible repetitive mucin regions) in linkage
disequilibrium (LD, defined as the tendency for genetic
variants located in close proximity on the same chromo-
some to occur together more often than expected by
chance) with rs35705950 affect the function of other
lung mucins.
Data from familial studies have significantly improved
our understanding of IPF pathogenesis. So far, mutations
in surfactant protein C, surfactant protein A2, MUC5B,
telomerase reverse transcriptase and telomerase RNA
component have been convincingly associated with FPF.
Mutations in these genes suggest that type II AEC and
cellular turn-over are central to the initiation and pro-
gression of the disease, the most plausible hypothesis
being that IPF occurs due to increased cell death in the
type II AEC population and/or inability of this cell popu-
lation to regenerate the alveolar epithelium after injury.
However, these mutations account for only 15% to 20%
of FPF cases and are even less frequent in sporadic IPF.
Thus, the majority of FPF cases have yet to have their
genetic mutations identified and it is likely that many
other genes are responsible across different families.
While the data on FPF are robust, at present there are
no genetic factors that have been consistently associated
with sporadic IPF [24]. Microarray analysis of gene
expression may ultimately contribute to elucidate disease
pathogenesis and target candidates for therapy, but they
are in an early phase of development [5].
Sarcoidosis
Sarcoidosis (ORPHA797) is a systemic inflammatory dis-
order of unknown origin characterized histologically by
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phocytes with associated non-caseating granuloma forma-
tion. According to the most convincing etiopathogenetic
hypothesis, sarcoidosis occurs in genetically susceptible
individuals as a consequence of exposure to one or more
environmental agents. Originally described as a chronic
granulomatous disorder of the skin, sarcoidosis can
involve any organ, although the pulmonary manifesta-
tions typically dominate with chest radiographs being
abnormal in up to 95% of patients. On the other hand,
pulmonary function tests are only abnormal in a minority
of patients, ranging from obstructive to restrictive pattern
with or without gas exchange defects. Absolute levels of
both macrophages and T-lymphocytes, the key immune
effector cells in sarcoidosis, are elevated in broncho-
alveolar lavage fluid (BALF) from patients, and a lympho-
cytosis with a CD4/CD8 ratio >3.5 is virtually diagnostic
[25,26].
Familial clustering of disease was first described in two
German sisters in 1923 and since then studies in various
populations have identified 2.7-17% of index cases as hav-
ing another affected family member [27-29]. ACCESS (A
Case–Control Etiologic Study of Sarcoidosis) estimated
the familial relative risk adjusted for age, gender, socio-
economic status and shared environment to be 4.7 [30],
confirming that family members of sarcoidosis patients
have a several-fold increased risk of disease compared
with the general population. In addition, monozygotic
twins are more likely than dizygotic twins to have the dis-
ease, although they may exhibit only minimal concor-
dance in terms of phenotypic features and outcomes [31].
Generally, sarcoidosis affects blacks more severely than
people of other races. In addition, extra-thoracic manifes-
tations are more prevalent in certain populations, such as
chronic uveitis in U.S. blacks and Japanese, lupus pernio -
a chronic rash consisting of papules and plaques usually
found on the face - in Puerto Ricans, Löfgren’s syndrome
in Scandinavians and myocardial involvement in Japanese.
On the other hand, Löfgren’s syndrome is uncommon in
blacks and Japanese [32-34].
The first reported association between sarcoidosis and
specific gene products was between Class I HLA-B8 anti-
gens and acute sarcoidosis [35]. Subsequently, HLA Class
II antigens - encoded by HLA-DRB1 and DQB1 alleles -
have been consistently associated with sarcoidosis [36-38].
However, based on the assumption that disease-associated
HLA molecules present specific antigenic peptides in such
a way that recognition by specific CD4+ T-lymphocytes
results in the initiation of an abnormal inflammatory
response, HLA class II genes are more likely to be involved
in sarcoidosis immunopathogenesis [39]. Nevertheless, it is
difficult to tease out which of the HLA Class II genes
represent the primary association owing to the tight and
highly variable degree of LD existing in this genomic area.Furthermore, in addition to conferring susceptibility to sar-
coidosis per se, HLA genotypes also predispose to specific
disease phenotypes, the most persuasive evidence being
the association between HLA-DQB1*0201 and DRB1*0301
and Löfgren’s syndrome - defined as the acute onset of
fever, erythema nodosum, bilateral hilar lymphadenopathy
and polyarthralgia [40]. Conversely, results of non-HLA
genes, though logical candidates based on their function,
such as tumor necrosis factor (TNF)-α, chemokines and
chemokine receptors, among others, have been largely
inconsistent [41,42].
Candidate-gene case–control association studies have
been commonly used for investigating rare diseases
where recruiting large numbers of pedigrees is often dif-
ficult. The distribution of genetic variations in the genes
of interest is compared between unrelated, affected indi-
viduals and matched healthy controls. This approach
requires prior knowledge of a gene, function and poly-
morphisms, and requires the investigator to have some
knowledge about the patho-physiology of the disease in
question and have reason to believe that the candidate
gene may influence the disease (“hypothesis-based
study”). On the other hand, genome-wide association
studies (GWAS) - a dense chip-based genotyping
approach covering much of the human genome - per-
mits an "agnostic" genome-wide comparison of gene-
variant prevalence between cases and controls. However,
because the results of GWAS are strongly influenced by
the population studied, different associations have been
reported in Caucasian and in African-American sarcoi-
dosis patients, as expected [43-46].
Polymorphisms within butyrophilin-like 2 (BTNL2)
gene - located in close proximity of the HLA complex on
chromosome 6 - have been associated with sarcoidosis
independently of HLA-DRB1 alleles [47,48]. BTNL2 is
thought to act as a negative co-stimulatory molecule, thus
non-functional BTNL2 could theoretically result in an
exaggerated T lymphocyte activation, compatible with the
proposed pathophysiology of sarcoidosis [49]. However, in
a number of other diseases, such as ulcerative colitis, mul-
tiple sclerosis, type 1 diabetes, rheumatoid arthritis, sys-
temic lupus erythematosus, Graves’ disease, tuberculosis,
leprosy, Crohn’s disease as well as in a study of sarcoido-
sis, the BTNL2 association appears to be “driven” by var-
ious HLA-DRB1 alleles in LD with the non-functional
rs2076530 A allele [50-54], highlighting the difficulty in
identifying the precise risk locus/i when HLA genes and
nearby loci in LD are considered simultaneously.
Disorders in which genetic testing is highly
recommended
Hermansky-Pudlak syndrome
Hermansky-Pudlak syndrome (HPS; ORPHA79430) is a
rare autosomal recessive disorder characterized by oculo-
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telet storage pool deficiency, and lung fibrosis [55]. The
disease, which is caused by defects of multiple cytoplasmic
organelles, including melanosomes, platelet-dense gran-
ules and lysosomes, has a prevalence of 1 in 1,800 in
Puerto Rico with only isolated case reports and small case
series having been reported in the rest of the world [56]. A
history of bruising, heavy menstrual cycles and fair skin
should raise the suspicion of HPS. Once the diagnosis has
been confirmed - by demonstration of the absence of pla-
telet dense bodies on whole-mount electron microscopy -
other family members should be screened for the syn-
drome and mutations within genes known to cause the
disease (HPS1-HPS8) searched for [57].
Lymphangioleiomyomatosis and Tuberous Sclerosis
Complex
Lymphangioleiomyomatosis (LAM; ORPHA538) is a rare
cystic lung disease characterized by an aberrant prolifera-
tion of smooth muscle-like cells (“LAM cells”), and asso-
ciated with renal angiomyolipomas and lymphatic spread
[58]. LAM can occur either as an isolated disorder or in
1-3% of patients with tuberous sclerosis complex (TSC;
ORPHA805), an autosomal dominant systemic disorder
resulting from mutations in the TSC1 and TSC2 gene and
characterized by epilepsy, widespread hamartomatous
lesions, renal angiomyolipomas, skin lesions and mental
retardation [59]. Both isolated LAM and LAM in the con-
text of TSC have a remarkable female gender restriction
with patients being affected generally in their reproductive
age, while TSC is equally distributed amongst genders.
Lung manifestations - in the form of profuse round, thin-
walled cysts - are indistinguishable in isolated LAM and
in LAM in the context of TSC [60]. Mutations in TSC1
are found in 15-30% of familial cases and 10-15% of spora-
dic cases, while mutations in TSC2 occur more frequently,
accounting for 75-80% of all sporadic cases [61,62]. Once
the diagnosis of LAM has been confirmed - by the
demonstration of the immunoreactivity of LAM cells with
HMB45 antibody - mutations in TSC1 and TSC2 genes
should be searched for. In fact, in patients with LAM rais-
ing in the context of TSC careful screening of family
members may reveal other affected - often asymptomatic
- individuals.
Birt-Hogg-Dubé syndrome
Birt-Hogg-Dubé (BHD; ORPHA122) syndrome is an
autosomal dominant disorder caused by loss-of-function
mutations in the folliculin (FLCN) gene and character-
ized by skin fibro-folliculomas, multiple lung cysts lined
by fibrous band (in up to 90% of cases), spontaneous
pneumothorax, and renal cancer [63]. BHD syndrome-
associated skin lesions include angiofibromas, which are
more typically associated with tuberous sclerosis. Inturn, tuberous sclerosis may manifest with pneu-
mothorax (caused by rupture of lung cysts), and renal
angiomyolipomas and should therefore be considered in
the differential diagnosis of BHD syndrome [64].
Because the skin lesions usually precede renal malignan-
cies by several years, a correct diagnosis may allow early
diagnosis of BHD syndrome and screening for renal can-
cer in other family members.
Dyskeratosis congenita
Dyskeratosis congenita (DC; ORPHA1775) is a rare sys-
temic disease usually presenting in the first or second
decade with bone marrow failure and a triad of muco-
cutaneous lesions including abnormal pigmentation, dys-
trophic nails, and oral leukoplakia [65]. DC is considered
a syndrome of premature aging as suggested by other
common features, such as premature graying of the hair,
pulmonary fibrosis (which develops in 20% of cases), tes-
ticular atrophy, cryptogenic cirrhosis, osteoporosis, and
increased risk of malignancy. In favor of this hypothesis,
DC was the first disease recognized to result from
impaired telomere maintenance [66]. Mode of inheri-
tance may be autosomal dominant, recessive, or X-
linked; the X-linked form results from a mutation in the
DKC1 gene, which encodes dyskerin, a telomerase-
associated protein. Although an identifiable mutation is
present in roughly 40% of cases, telomere length is uni-
formly reduced in patients with DC. In addition, muta-
tions within TERT and TERC in DC kindreds have been
associated with genetic anticipation - the occurrence of
more severe and earlier onset disease in later generations
secondary to progressive telomere shortening [17].
Pulmonary involvement from rare diseases represents
one end of a spectrum of clinical manifestations. Making
the correct diagnosis is crucial for both preventing fatal
complications in affected subjects and early diagnosing
the disease in other family members.
What is the utility of genetic testing in sarcoidosis and
IPF?
The utility of genetic testing stems on the possibility to
predict disease development in susceptible individuals.
However, the risk-to-benefit ratio for genetic screening
is related to its pre-test probability and should carefully
be evaluated for each disorder. As such, genetic testing
is strongly recommended, for instance, in BHD syn-
drome because there is no locus heterogeneity (only one
culprit gene is known) and the presence of a mutation
advocates screening for renal cancer, which complicates
10% of cases [67]. Conversely, routine genetic testing is
of unproven benefit in sporadic LAM and is not recom-
mended by current guidelines [68].
In highly specialized referral centres for sarcoidosis,
patients presenting with Löfgren’s syndrome are routinely
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haplotype. In fact, in addition to displaying typical clinical
features - acute onset, bilateral hilar lymphadenopathy,
erythema nodosum and/or bilateral ankle arthritis - this
subset of patients can be further characterized according
to the carriage of DR3 as disease resolution occurs in
almost every DR3-positive patient but only in half of those
who do not carry this haplotype [69].
Testing for rare and common variants is different:
mutations within TERT, TERC, SFTPC and SFTPA2 are
individually very rare, but have a large effect in the kin-
dreds in which they are found. In fact, inheritance of
these mutations segregate with pulmonary fibrosis in a
Mendelian autosomal dominant pattern with reduced
penetrance [70]. Conversely, the minor allele of the
MUC5 rs35705950 polymorphism is present in 9% of
the normal population. As such, testing for the MUC5
rs35705950 mutant allele could be valuable only in
selected individuals with high pre-test risk of developing
the disease (i.e., members of families subject to idio-
pathic interstitial pneumonia), as the positive predictive
value of such testing would be very low.
Results of genetic testing are often complex and diffi-
cult to interpret in isolation. Genetic counselling is
essential in providing a personalized interpretation of
the results, with special emphasis on the meaning of sus-
ceptibility, the risk for other family members to develop
the disease and the limited predictive value of positive
and negative results. Once provided with this informa-
tion, an individual can make more informed decisions
regarding their healthcare. In addition, those found to be
at increased risk should utterly avoid any (further)
potentially harmful exposures.
Should a respiratory physician consider routine genetic
testing in sarcoidosis and IPF? At present, susceptibility
testing for these diseases is neither widely available nor
recommended by current guidelines in patients with
familial or sporadic disease as part of their clinical eva-
luation. Similarly, there is no evidence that unaffected
family members should be screened for asymptomatic
disease. This is particularly true for dominant mutations
of variable penetrance where prediction of risk is proble-
matic. Furthermore, it is unclear whether early diagnosis
makes the disease more amenable to therapeutic inter-
vention [5]. Considering the average costs of genetic test
and the possibility of identifying variants of unknown
significance, genetic screening should be limited to
selected disorders, i.e., those displaying no or low genetic
locus heterogeneity and for which a specific diagnosis
would impact patient management.
Future directions
The recent development of next generation sequencing
technologies (whole genome, whole exome and targetedregion sequencing) is likely to rapidly increase the num-
ber of genetic variants associated with sarcoidosis and
IPF, including rare risk alleles, which cannot be identi-
fied by genotyping. In fact, a significant amount of herit-
ability in sarcoidosis and IPF could be accounted for by
rare variants each with moderate to high penetrance
[71]. Genetic data should be integrated with gene
expression and epigenetic data in order to prioritize can-
didates for further studies. Once prioritized, candidate
genes will then need to be evaluated for their role in dis-
ease pathogenesis (i.e., in cellular and animal studies). If
genetic links with a disease are clearly defined, then the
pathways involved with these genes and gene products
could be specifically targeted with potentially tremen-
dous therapeutic implications. The success of sirolimus -
a mammalian target of rapamycin (mTOR) signaling
inhibitor - in stabilizing lung function, reducing respira-
tory symptoms and improving quality of life in tuberous
sclerosis/LAM patients is proof of concept that therapy
targeting specific defective genetic and biochemical
pathways can be successful [72]. The hope is that treat-
ment strategies targeting individual aberrant genes will
be soon available for other DPLD with genetic signature.
We have incomplete knowledge of ethnic differences
in genetic associations as well as limited insight in gene-
gene and gene-environment interactions. Future studies
should address these deficiencies. To this end, participa-
tion in international consortia of institutions - with the
intention of recruiting larger numbers of patients - is
critical. Likewise, it is imperative that meticulous data-
bases of phenotypically well-defined patients are contin-
ued to be constructed as this will significantly reduce
the number of subjects required to show meaningful
genetic associations. In fact, relatively small studies
based on accurate genotyping with exhaustively defined
phenotype criteria are equally, if not more so, able to
detect the same effect as larger studies of a less stringent
design. It is possible that genetics extends to determin-
ing not only overall susceptibility but also distinct phe-
notypic routes, and that genes responsible for the
development of a given disease are different from those
determining its phenotypic expression. As such, it is
essential that genetic data are always analyzed according
to clinical phenotype and not limited to a “generic” dis-
ease susceptibility. Last, but not least, data regarding
incidence and prevalence of familial cases of pulmonary
fibrosis and sarcoidosis are incomplete, at best, as the
disease may be asymptomatic, thus undiagnosed. Future
studies should also address and clarify this issue.
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